Literature DB >> 11906756

Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres.

J E Rosas1, J L Pedraz, R M Hernández, A R Gascón, M Igartua, F Guzmán, R Rodríguez, J Cortés, M E Patarroyo.   

Abstract

Single dose immunisation is a major goal in vaccine design. The purpose of this study was the development of a single dose delivery system for the SPf66 malaria vaccine, based on this antigen's microencapsulation in PLGA microspheres by double emulsion method. Results indicate that a single immunisation in mice and monkeys with the SPf66 malaria vaccine, encapsulated in a mixture of two formulations of PLGA microspheres, induced a remarkably high and long-lasting immune response as assessed by ELISA and Western Blott. This immune response was associated with a good protective capacity in Aotus monkeys, after experimental challenge, indicating that antigen integrity lasted following the microencapsulation process. PLGA biodegradable microspheres thus serve as an effective delivery system for the design of a single dose immunisation vaccine, such as the SPf66 synthetic malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906756     DOI: 10.1016/s0264-410x(01)00508-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys.

Authors:  Juan E Baquero; Santiago Miranda; Oscar Murillo; Heidy Mateus; Esperanza Trujillo; Carlos Suarez; Manuel E Patarroyo; Carlos Parra-López
Journal:  Immunogenetics       Date:  2006-05-30       Impact factor: 2.846

3.  BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Authors:  Jooeun Bae; Neha Parayath; Wenxue Ma; Mansoor Amiji; Nikhil Munshi; Kenneth C Anderson
Journal:  Leukemia       Date:  2019-08-19       Impact factor: 11.528

Review 4.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

6.  Identifying and structurally characterizing CD1b in Aotus nancymaae owl monkeys.

Authors:  Fabio Castillo; Carlos Guerrero; Esperanza Trujillo; Gabriela Delgado; Pilar Martinez; Luz M Salazar; Paola Barato; Manuel E Patarroyo; Carlos Parra-López
Journal:  Immunogenetics       Date:  2004-09-10       Impact factor: 2.846

7.  Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.

Authors:  Angel M Carcaboso; Rosa M Hernández; Manuela Igartua; Jaiver E Rosas; Manuel E Patarroyo; José L Pedraz
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

8.  An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.

Authors:  Aiala Salvador; Manoli Igartua; Rosa Maria Hernández; José Luis Pedraz
Journal:  J Drug Deliv       Date:  2011-06-15

9.  Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.

Authors:  Claudia Carvalho-Queiroz; Ruth Nyakundi; Paul Ogongo; Hitler Rikoi; Nejat K Egilmez; Idle O Farah; Thomas M Kariuki; Philip T LoVerde
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

10.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.